Febrile Neutropenia
5 original drugsFebrile Neutropenia has 5 FDA-approved novel treatments, led by Amgen across 3 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Febrile Neutropenia Market Leaders
Companies with the most FDA-approved novel Febrile Neutropenia drugs.
Febrile Neutropenia Treatments by Mechanism
Top 1 mechanisms across 1 industry trials with a known mechanism of action.
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Febrile Neutropenia Clinical Pipeline by Phase
29 industry-sponsored trials across 16 sponsors
Novel Febrile Neutropenia Drugs by Company (New molecular entities)
4 companies have an FDA-approved novel drug for Febrile Neutropenia.
Reformulations (2 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Febrile Neutropenia Drug Targets
Molecular targets of approved and investigational Febrile Neutropenia drugs — 3 targets tracked.
Biosimilars (11 BLA approved) Click to expand
Biosimilars are biological products highly similar to FDA-approved reference biologics with no clinically meaningful differences in safety, purity, or potency.
Generic Drugs (2 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs